Leukemic Stem Cell Ablation
AssigneeChemGenex Pharmaceuticals, Inc.
InventorDennis Brown
Life of this patent
Estimating the term…
Abstract
A method for treating a leukemia patient that is resistant to a thymidine kinase inhibitor (TKI) other than imantinib comprising administering a cephalotaxine to said patient until said patient demonstrates a hematological or cytological response to said leukemia.
Claims25
1-19. (canceled)
A method for treating a patient with leukemia that is resistant to dasatinib, said method comprising:
- administering omacetaxine mepesuccinate to said patient until said patient demonstrates a hematological or cytological response.
A method for treating a patient with leukemia that is resistant to bosutinib, said method comprising:
- (a) administering omacetaxine mepesuccinate to said patient until said patient demonstrates a hematological or cytological response.
A method for treating a patient with leukemia that is resistant to at least one of dasatinib or bosutinib, said method comprising administering omacetaxine mepesuccinate to said patient.
A method for treating a patient with leukemia that is resistant to dasatinib or bosutinib, said method comprising:
- (a) administering omacetaxine mepesuccinate to said patient in an amount of about 1.0 to about 5.0 mg/m2.
Dependencies are inferred from the claim text.